Drugs / sotalol
last change 3 days ago re-read 2 minutes ago

sotalol

Small molecule targets ADRB1, ADRB2, KCNH2 via inhibition

Developed for
atrial fibrillation · ventricular tachycardia · ventricular fibrillation · cardiac rhythm disease · sudden cardiac arrest · atrial flutter · cardiac arrest · paroxysmal atrial fibrillation
+5 more · coronary artery disorder · diastolic heart failure · heart failure · hydrops fetalis · persistent atrial fibrillation
Investigated by
National Heart, Lung, and Blood Institute (NHLBI) · Abbott Medical Devices · Duke Clinical Research Institute · Medtronic · Asan Medical Center · Assistance Publique - Hôpitaux de Paris
+31 more · Baylis Medical Company · Beijing CTSmed Co. Ltd · Biosense Webster, Inc. · Connolly, Stuart, M.D. · Duke University · IRCCS Ospedale San Raffaele · IRCCS San Raffaele · Inje University Ilsan Paik Hospital · Jason Andrade · Kansas City Heart Rhythm Research Foundation · Keimyung University Dongsan Medical Center · Korea University Anam Hospital · Korea University Guro Hospital · Mayo Clinic · Medtronic (Shanghai) Management Co. Ltd. · Munson Medical Center · Ottawa Heart Institute Research Corporation · Samsung Medical Center · Shengjing Hospital · Sinchon Severance Hospital, Yonsei University College of Medicine · Texas Cardiac Arrhythmia Research Foundation · The Catholic University of Korea · University of Illinois at Chicago · University of Pennsylvania · University of Sao Paulo General Hospital · University of Utah · University of Washington · Valley Health System · Vanderbilt University Medical Center · Wonju Severance Christian Hospital · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Regulatory milestones approvals, filings & regulatory actions · 4 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (2) US (FDA) SOTALOL HYDROCHLORIDE 2020-03-06 – 2025-07-23 fda.gov
Label expansion US (FDA) BETAPACE 2001-10-01 fda.gov
Approved US (FDA) BETAPACE 1992-10-30 fda.gov

Trials 20 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00773201 Feb 2008 → Mar 2012 Assistance Publique - Hôpitaux de Paris Completed No outcome recorded
Phase 35 trials
Phase 3 NCT04208997 Dec 2019 → Jun 2021 ventricular tachycardia Vanderbilt University Medical Center Terminated No outcome recorded
Phase 3 NCT00000556 Mar 1995 → Sep 2002 atrial fibrillation National Heart, Lung, and Blood Institute (NHLBI) Completed No outcome recorded
Phase 3 NCT00000531 Sep 1992 → Aug 2002 sudden cardiac arrest, ventricular fibrillation, ventricular tachycardia National Heart, Lung, and Blood Institute (NHLBI) Completed No outcome recorded
Phase 3 NCT00000464 Apr 1987 → Dec 1992 cardiac arrest, myocardial infarction, ventricular fibrillation University of Washington Completed No outcome recorded
Phase 3 NCT00000518 Jul 1985 → Dec 1992 sudden cardiac arrest, ventricular fibrillation, ventricular tachycardia University of Utah Completed No outcome recorded
Phase 48 trials
Phase 4 NCT04473807 Jan 2021 → Apr 2022 atrial fibrillation Kansas City Heart Rhythm Research Foundation Unknown No outcome recorded
Phase 4 NCT02347111 Dec 2020 → Jun 2026 overdue atrial fibrillation University of Illinois at Chicago Recruiting No outcome recorded
Phase 4 NCT05418036 Oct 2020 → Feb 2023 cardiac rhythm disease University of Sao Paulo General Hospital Unknown No outcome recorded
Phase 4 NCT03895411 Aug 2019 → Dec 2020 cardiac rhythm disease Shengjing Hospital Unknown No outcome recorded
Phase 4 NCT02145546 May 2014 → May 2017 atrial fibrillation Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Unknown No outcome recorded
Phase 4 NCT01505296 Dec 2011 → Jan 2014 atrial fibrillation Valley Health System Withdrawn No outcome recorded
Phase 4 NCT00340314 Jan 2005 → May 2006 atrial fibrillation IRCCS San Raffaele Completed No outcome recorded
Phase 4 NCT00257959 Jan 2001 → Oct 2004 ventricular tachycardia Connolly, Stuart, M.D. Completed No outcome recorded
Phase not applicable6 trials
NCT06669299 Jun 2025 → Dec 2027 expected ventricular tachycardia IRCCS Ospedale San Raffaele Recruiting No outcome recorded
NCT07447297 Jan 2024 → Dec 2027 expected atrial fibrillation, atrial flutter Samsung Medical Center Recruiting No outcome recorded
NCT02825979 Jan 2017 → Sep 2022 atrial fibrillation Jason Andrade Unknown No outcome recorded
NCT01576042 May 2012 → May 2014 ventricular tachycardia Duke University Terminated No outcome recorded
NCT00408200 Nov 2006 → Apr 2008 paroxysmal atrial fibrillation University of Pennsylvania Completed No outcome recorded
NCT00578617 Sep 2006 → Feb 2009 atrial fibrillation Mayo Clinic Completed No outcome recorded
Also used as a comparator or background therapy in 34 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02153437 Comparator Oct 2014 → Oct 2016 atrial fibrillation Bristol-Myers Squibb Terminated No outcome recorded
Phase 21 trial
Phase 2 NCT01709682 Comparator Nov 2007 → Jan 2012 paroxysmal atrial fibrillation Meshalkin Research Institute of Pathology of Circulation Completed No outcome recorded
Phase 38 trials
Phase 3 NCT05939076 Comparator Aug 2023 → Dec 2027 expected persistent atrial fibrillation Region Örebro County Not yet recruiting No outcome recorded
Phase 3 NCT04037397 Comparator Sep 2019 → Oct 2024 atrial fibrillation University of Pennsylvania Completed No outcome recorded
Phase 3 NCT02624765 Comparator Feb 2016 → Mar 2024 atrial flutter, hydrops fetalis Edgar Jaeggi Completed No outcome recorded
Phase 3 NCT01798277 Comparator Apr 2013 → Jun 2015 coronary artery disorder, ventricular tachycardia Newmarket Electrophysiology Research Group Inc Withdrawn No outcome recorded
Phase 3 NCT00589303 Comparator Dec 2007 → Jul 2011 atrial fibrillation, heart failure Mayo Clinic Terminated No outcome recorded
Phase 410 trials
Phase 4 NCT07405671 Comparator Sep 2026 → Dec 2029 expected atrial fibrillation, coronary artery disorder Universitaire Ziekenhuizen KU Leuven Not yet recruiting No outcome recorded
Phase 4 NCT04757584 Comparator Apr 2021 → Apr 2023 diastolic heart failure Weill Medical College of Cornell University Completed No outcome recorded
Phase 4 NCT04767061 Comparator Apr 2021 → Apr 2022 diastolic heart failure Weill Medical College of Cornell University Completed No outcome recorded
Phase 4 NCT02830360 Comparator Oct 2016 → Jun 2024 ventricular tachycardia John Sapp Completed No outcome recorded
Phase 4 NCT02303639 Comparator Apr 2015 → Jun 2017 myocardial infarction, ventricular tachycardia Central Finland Hospital District Unknown No outcome recorded
Phase not applicable14 trials
NCT07445334 Comparator Mar 2026 → Sep 2027 expected cardiac rhythm disease Western Sydney Local Health District Not yet recruiting No outcome recorded
NCT06322017 Comparator Apr 2024 → Apr 2030 expected atrial fibrillation Nantes University Hospital Recruiting No outcome recorded
NCT06096337 Comparator Dec 2023 → Feb 2026 overdue persistent atrial fibrillation Boston Scientific Corporation Active not recruiting No outcome recorded
NCT05790707 Comparator Apr 2023 → Jan 2027 expected cognitive impairment with or without cerebellar ataxia, persistent atrial fibrillation Poitiers University Hospital Recruiting No outcome recorded
NCT04942834 Comparator Oct 2021 → Jul 2025 persistent atrial fibrillation Ruijin Hospital Unknown No outcome recorded

Evidence & citations 26 cited values

Every value below carries the sentence it was read from. 56 sources stand behind the page.

FieldValueCited text
Known as Sotalol “Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as...” NCT01411371
53

“Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according...” NCT02825979

“Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according...” NCT05514860

“Patients will be prescribed antiarrhythmic drugs (either amiodarone or sotalol based on specific clinical presentation, including medical history, functional class, ejection...” NCT02830360

“The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.” NCT01477983

“Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.” NCT02114528

“* procainamide * quinidine * disopyramide * propafenone * flecainide * sotalol * dofetilide * amiodarone” NCT00589303

“Amiodarone; Dronaderone; Sotalol Beta blockers; Calcium channel blockers; Flecainide; or Propafenone.” NCT02459574

“maximum tolerable doses of another ADT, which included flecainide, sotalol, and amiodarone.” PMID 17161267 Oct 2006

“clinical protocol suggests sotalol (which has both AAD and BB properties) 80mg twice daily” NCT07445334

“Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed.” NCT05790707

“flecainide, propafenone, pilsicainide, sotalol, amiodarone, dronedarone and so on” NCT07447297

“Propafenone or Flecanide or Sotalol or Dofetilide or Dronedarone or Amiodarone.” NCT04037397

“Amiodarone (or sotalol) tablet by mouth for the duration of the study” NCT02303639

“Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg” NCT00911508

“propafenone, flecainide, sotalol, dofetilide” NCT01505296

“being commenced on sotalol 80mg twice/day.” NCT05524077

Sotalol: Sotalex or Sotalol EG 80mg b.i.d.” NCT03437356

“Continuation of amiodarone or sotalol.” NCT04208997

“Amiodarone or sotalol therapy” NCT03734562

Sotalol 240mg” NCT00578617

sotalolNCT04757584

sotalolNCT04767061

NCT00773201

NCT07405671

NCT00000518

NCT06322017

NCT02624765

NCT01798277

NCT00000464

NCT02145546

NCT05418036

NCT00408200

NCT02389218

NCT02347111

NCT02294955

NCT00000556

NCT00000531

NCT04942834

NCT00257959

NCT01709682

NCT05939076

NCT04473807

NCT00540787

NCT01576042

NCT01780311

NCT02153437

NCT03895411

NCT06669299

NCT00035451

NCT06096337

NCT03845010

NCT00523978

NCT00007605

Known as Beta-cardone ChEMBL registry synonym — accepted as the source's own label CHEMBL471
Known as Betapace ChEMBL registry synonym — accepted as the source's own label CHEMBL471
Known as Betapace af ChEMBL registry synonym — accepted as the source's own label CHEMBL471
Known as C07AA07 ChEMBL registry synonym — accepted as the source's own label CHEMBL471
Known as Darob ChEMBL registry synonym — accepted as the source's own label CHEMBL471
Known as Darob mite ChEMBL registry synonym — accepted as the source's own label CHEMBL471
Known as DL-MJ-1999 ChEMBL registry synonym — accepted as the source's own label CHEMBL471
Known as Dl-sotalol ChEMBL registry synonym — accepted as the source's own label CHEMBL471
Known as MJ 1999 ChEMBL registry synonym — accepted as the source's own label CHEMBL471
Known as NSC-337251 ChEMBL registry synonym — accepted as the source's own label CHEMBL471
Known as NSC-760358 ChEMBL registry synonym — accepted as the source's own label CHEMBL471
Known as Sorine ChEMBL registry synonym — accepted as the source's own label CHEMBL471
Known as Sotacor “dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™” NCT05939076
1

“Amiodarone (Cordarone) or Sotalol (Sotacor)” NCT02830360

Known as Sotalex “Sotalol: Sotalex or Sotalol EG 80mg b.i.d.” NCT03437356
Known as Sotalol EG “Sotalol: Sotalex or Sotalol EG 80mg b.i.d.” NCT03437356
Known as Sotalol hcl ChEMBL registry synonym — accepted as the source's own label CHEMBL471
Known as SOTALOL HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL471
Known as Sotalol hydrochloride component of sotylize ChEMBL registry synonym — accepted as the source's own label CHEMBL471
Known as Sotylize ChEMBL registry synonym — accepted as the source's own label CHEMBL471
Action Inhibit “Beta-2 adrenergic receptor antagonist” CHEMBL471
2

“Beta-1 adrenergic receptor antagonist” CHEMBL471

“HERG blocker” CHEMBL471

Modality Small molecule CHEMBL471
Route Oral “an oral 80mg sotalol dose” PMID 28800628 Aug 2017
Target ADRB1 “Beta-1 adrenergic receptor antagonist” CHEMBL471
Target ADRB2 “Beta-2 adrenergic receptor antagonist” CHEMBL471